Pros and Cons of Retatrutide: Trial Evidence

Retatrutide is an investigational triple hormone receptor agonist developed by Eli Lilly, acting on the GLP-1, GIP and glucagon receptors. It holds no marketing authorisation in the UK or elsewhere and is available only within authorised clinical trials. This article sets out the pros and cons of retatrutide as reported in clinical trial data to date, covering its pharmacology, trial findings, observed side effects, and the limitations of the current evidence base, to help readers understand where the research stands.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide is an unlicensed investigational compound with no UK marketing authorisation; it is available only to participants in authorised clinical trials and cannot be obtained through a pharmacy or clinic.

Retatrutide holds no marketing authorisation in the UK or anywhere else, meaning it is not a licensed medicine and cannot be advertised, and cannot be legally prescribed or supplied outside an authorised clinical trial.^[1][2] It is an investigational compound developed by Eli Lilly that acts simultaneously on three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[4][5] This triple agonist mechanism distinguishes it pharmacologically from currently licensed treatments such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP and GLP-1 receptor agonist), though no head-to-head trials have been conducted and no direct comparisons can be drawn.^[23][24]

Because retatrutide is unlicensed, it is available only to participants enrolled in an authorised clinical trial. It cannot be obtained through a pharmacy, a private clinic or an online consultation, and no UK launch date has been announced. The MHRA has warned that promoting unlicensed medicines, including inviting people to register interest or join lists ahead of any future availability, is not permitted.^[2][3] Any product sold online and described as retatrutide is not a licensed medicine and may be falsified, posing a serious risk to patient safety. People interested in weight management or type 2 diabetes treatment are encouraged to speak with their GP about licensed options that are currently available on the NHS or privately.

What have clinical trials reported about retatrutide so far?

A 2023 Phase 2 trial reported a mean body weight reduction of approximately 24% at the highest dose over 48 weeks; Phase 3 trials are ongoing but the full dataset is not yet complete.

The most detailed early data on retatrutide come from a Phase 2 dose-ranging trial reported in the New England Journal of Medicine in 2023, which enrolled adults with obesity over 48 weeks. In that trial, participants receiving the highest dose studied achieved a mean body weight reduction of approximately 24% from baseline, a finding that attracted considerable scientific interest. A separate Phase 2 trial in adults with type 2 diabetes also reported reductions in HbA1c alongside weight loss.^[6][7]

Phase 3 trials are now reporting results. The TRANSCEND-T2D-1 study, examining retatrutide in adults with type 2 diabetes, has been published in a peer-reviewed journal, and readouts from the TRIUMPH programme in people with obesity have been presented at major scientific congresses.^[10][11] These Phase 3 findings extend the evidence base beyond the earlier Phase 2 work, though the full dataset across all planned trials, including long-term cardiovascular outcomes and multi-year safety follow-up, is not yet complete. Trial findings in selected populations under controlled conditions should not be interpreted as outcomes an individual would expect to achieve.

Until the complete Phase 3 programme has been reviewed by regulators such as the MHRA and a marketing authorisation is sought and granted, retatrutide remains an investigational compound. The regulatory outcome is not predetermined, and no timeline for UK availability can be given.

What side effects and safety concerns have been observed?

The most common side effects are gastrointestinal (nausea, vomiting, diarrhoea, constipation); heart rate increases, pancreatitis risk, thyroid signals and gallbladder disease also require ongoing evaluation.

The side effects observed with retatrutide in clinical trials are broadly consistent with those seen with other medicines in the GLP-1 receptor agonist class, though the glucagon receptor component introduces additional considerations. The most commonly reported adverse events in the Phase 2 trial were gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation. These effects were generally dose-dependent and most frequent during dose escalation, which is a pattern recognised across this drug class.

Heart rate increases were also observed in trial participants, a finding that has been noted with other GLP-1 and GIP receptor agonists and which requires ongoing evaluation in larger populations.^[4][5] As with licensed medicines in this class, acute pancreatitis has been reported with related agents, including post-marketing reports of necrotising pancreatitis; the relevance of this to retatrutide will need to be assessed through the full Phase 3 programme and any future regulatory review.^[13][14] Rodent studies with GLP-1 receptor agonists have identified C-cell changes in the thyroid, though the human relevance of this finding remains uncertain.^[15][16] Incretin-based therapies have also been associated with gallbladder and biliary disease in observational data, and this signal will require evaluation in the retatrutide programme.^[17][18] In people with pre-existing pre-proliferative or proliferative diabetic retinopathy, rapid improvement in glycaemic control has been associated with transient worsening of retinopathy with related agents; this subgroup warrants particular attention in ongoing trials.

Trial participants who experience adverse events should report them to the trial team or sponsor in accordance with the study protocol. Suspected side effects can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Anyone who believes they have obtained a product described as retatrutide outside a clinical trial and experiences adverse effects should contact their GP or, if symptoms are severe, call 999 and inform the emergency clinicians that they are enrolled in a clinical trial or have taken an unlicensed substance.

What are the known limitations of the current research?

The full Phase 3 dataset is incomplete, long-term cardiovascular and safety outcomes are unknown, trial populations have been relatively homogeneous, and no head-to-head comparisons with licensed treatments exist.

Although Phase 3 data are now emerging, the full evidence base for retatrutide remains incomplete. The 48-week Phase 2 weight-management trial does not capture long-term outcomes such as cardiovascular events, sustained weight maintenance or the safety profile over several years. While Phase 3 readouts from TRANSCEND-T2D-1 and the TRIUMPH programme have been reported, the complete dataset across all planned trials has not yet been published in peer-reviewed literature, and regulators including the MHRA require a comprehensive submission before granting a marketing authorisation.

The trial populations studied so far have been relatively homogeneous, and it is not yet known how retatrutide performs across the full range of people who might eventually be eligible, including those with significant comorbidities, older adults or people from diverse ethnic backgrounds. There are also no published data on use during pregnancy or breastfeeding; participants in retatrutide trials are excluded if they are pregnant, breastfeeding or planning a pregnancy, and contraception requirements apply during participation, meaning that safety in these groups is entirely unknown at this stage.

Finally, because no head-to-head trials comparing retatrutide with licensed treatments have been conducted, any claims about relative efficacy are speculative. The Phase 3 TRIUMPH and TRANSCEND trials will provide substantially more robust data, but until those results are fully reviewed by regulators and a marketing authorisation is sought and granted, retatrutide remains an investigational compound. No timeline for UK availability can be given, and the regulatory outcome is not predetermined.

Frequently Asked Questions